← All trials
NCT05338632
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 16, 2022
- Primary completion
- May 1, 2024
- Completion date
- May 30, 2024
- First posted
- Apr 21, 2022
- Last posted
- Aug 16, 2022
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leiden UniversityLead sponsor
- Leiden UniversityOverall official - principal investigator
- Leiden UniversityReponsible party - principal investigator
- Food and Drug AdministrationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.